BeOne Medicines Ltd. (ONC) operating KPIs
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)
Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –
BeOne Medicines amgen Co-Development Expense Charged to R&D ($M) ($M)
Form 10-Q / 10-K Collaboration Note & MD&A
Latest, Q2 2026
30.3
Period ended Jun 30, 2026
Change on a year earlier
+14.8%
26.4 in Q2 2025
History
26 quarters
Since Q1 2020
Sources
21
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Amgen Co-Development Expense Charged to R&D ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 30.3 | +14.8% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 29.4 | +42.0% | Form 10-Q (filed 2026-05-06) ↗ |
| Q4 2025 | Dec 31, 2025 | 26.9 | +21.2% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2025 | Sep 30, 2025 | 30.1 | +77.1% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2025 | Jun 30, 2025 | 26.4 | +17.3% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2025 | Mar 31, 2025 | 20.7 | +53.3% | Form 10-Q (filed 2026-05-06) ↗ |
| Q4 2024 | Dec 31, 2024 | 22.2 | +62.0% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2024 | Sep 30, 2024 | 17 | +4.3% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2024 | Jun 30, 2024 | 22.5 | +309.1% | Form 10-Q (filed 2025-08-06) ↗ |
| Q1 2024 | Mar 31, 2024 | 13.5 | -24.2% | Form 10-Q (filed 2025-05-07) ↗ |
| Q4 2023 | Dec 31, 2023 | 13.7 | -48.7% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2023 | Sep 30, 2023 | 16.3 | -36.1% | Form 10-Q (filed 2024-11-12) ↗ |
| Q2 2023 | Jun 30, 2023 | 5.50 | -77.5% | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2023 | Mar 31, 2023 | 17.8 | -20.5% | Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2022 | Dec 31, 2022 | 26.7 | -12.2% | Form 10-K (filed 2025-02-27) ↗ |
| Q3 2022 | Sep 30, 2022 | 25.5 | -14.1% | Form 10-Q (filed 2023-11-09) ↗ |
| Q2 2022 | Jun 30, 2022 | 24.4 | -11.9% | Form 10-Q (filed 2023-08-02) ↗ |
| Q1 2022 | Mar 31, 2022 | 22.4 | -18.8% | Form 10-Q (filed 2023-05-04) ↗ |
| Q4 2021 | Dec 31, 2021 | 30.4 | +3.1% | Form 10-K (filed 2024-02-26) ↗ |
| Q3 2021 | Sep 30, 2021 | 29.7 | -3.6% | Form 10-Q (filed 2022-11-09) ↗ |
| Q2 2021 | Jun 30, 2021 | 27.7 | -2.1% | Form 10-Q (filed 2022-08-08) ↗ |
| Q1 2021 | Mar 31, 2021 | 27.6 | -2.8% | Form 10-Q (filed 2022-05-09) ↗ |
| Q4 2020 | Dec 31, 2020 | 29.5 | – | Form 10-K (filed 2023-02-27) ↗ |
| Q3 2020 | Sep 30, 2020 | 30.8 | – | Form 10-Q (filed 2021-11-04) ↗ |
| Q2 2020 | Jun 30, 2020 | 28.3 | – | Form 10-Q (filed 2021-08-05) ↗ |
| Q1 2020 | Mar 31, 2020 | 28.4 | – | Form 10-Q (filed 2021-05-06) ↗ |
Cite this data
StockData. (2026). BeOne Medicines Amgen Co-Development Expense Charged to R&D ($M) ($M), quarterly Q1 2020–Q2 2026 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/rd_ext_amgen_codev
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.